C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT

C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01691300

Acronym

ACTMM

Enrollment

Registered

2012-09-24

Start date

2011-05-31

Completion date

2015-11-30

Last updated

2015-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

C11-acetate PET/CT, Multiple myeloma, Pretreatment staging, Response assessment

Brief summary

Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).

Interventions

OTHERACT PET/CT

Old tracer but new indication

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* at least 20 years of age * previously untreated * complete pre-treatment clinical staging including bone marrow examination * written informed consent to participate in the study

Exclusion criteria

* concurrent active malignant tumor(s) * pregnant or breast feeding women * non-compliant to PET/CT or to MRI * marked renal impairment (contraindicated for contrast-enhanced MRI)

Design outcomes

Primary

Measure	Time frame	Description
Pretreatment lesion detection	Within 2 weeks before initiation of therapy	Reference standards: bone marrow examination and whole-body dynamic contrast-enhanced MRI

Secondary

Measure	Time frame	Description
Post-induction response assessment	Approximately 4 months after initiation of therapy depending on the regimen	Reference standard: clinical response based on International Uniform Criteria and bone marrow examination if any
Post-ASCT response assessment	Approximately 3 months after ASCT	Reference standard: clinical response based on International Uniform Criteria and bone marrow examination if any

Other

Measure	Time frame	Description
Progression free survival	With 2 years of follow-up time	Based on clinical follow-up (M-protein or FLC assay, bone marrow examination or imaging findings)

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026